搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
1 天
on MSN
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...
1 天
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...
BioPharma Dive
2 天
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...
in.investing.com on MSN
1 天
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...
BioPharma Dive
1 天
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
1 天
on MSN
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
1 天
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...
Wall Street Journal on MSN
1 天
Sanofi Profit, Sales Beat Estimates
Sanofi SAN-1.02%decrease; red down pointing triangle posted better-than-expected earnings and sales in the third quarter, ...
1 天
Sanofi beats expectations with bumper third-quarter earnings
Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...
FiercePharma
1 天
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
1 天
Sanofi Reports Strong Q3 Growth and Raises EPS Guidance
Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...
The Pharma Letter
1 天
Sanofi outpaces expectations in third quarter 2024
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈